ホーム › 非小細胞肺癌 › カリフォルニア州 › Irvine
Irvine、CAにおける非小細胞肺癌の臨床試験
Irvineとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する25件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144, Irvine
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第2/3相
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928, Irvine
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Kaiser Permanente-Irvine, Irvine
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- City of Hope at Irvine Lennar, Irvine
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
被験者募集中第2相
- City of Hope 1, Irvine
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
被験者募集中第2/3相
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
被験者募集中第1相
- Hoag Memorial Hospital Presbyterian, Irvine
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- UCI Health-CIACC, Irvine
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Irvine
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
被験者募集中第1/2相
- City of Hope, Irvine
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
被験者募集中第2相
- City of Hope at Irvine Lennar, Irvine
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
被験者募集中第1/2相
- The Regents of the University of California - Irvine, CA Campus, Irvine
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
被験者募集中第1相
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
被験者募集中第3相
- City of Hope at Irvine Lennar, Irvine
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- City of Hope - Lennar, Irvine
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
Study of XB010 in Subjects With Solid Tumors
被験者募集中第1相
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- City of Hope at Irvine Lennar, Irvine
- Kaiser Permanente-Irvine, Irvine
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
被験者募集中第2相
- City of Hope at Irvine Lennar, Irvine
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- University of California, Irvine, Irvine
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
被験者募集中第1相
- City of Hope at Irvine Lennar, Irvine
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
被験者募集中第2相
- City of Hope at Irvine Lennar, Irvine
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Irvine
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Irvineにおける他の研究
- 乳がん23件の研究
- がん（全種類）17件の研究
- 転移性癌16件の研究
- 肺がん15件の研究
- 多発性骨髄腫14件の研究
- 前立腺がん14件の研究
- 卵巣がん12件の研究
- 頭頸部扁平上皮癌11件の研究
- 膀胱癌11件の研究
- アルツハイマー病11件の研究
- 大腸癌10件の研究
- 膵臓がん10件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。